Systemic Bevacizumab for Severe Recurrent Respiratory Papillomatosis

被引：4
作者：
Tatineni, Swetha [1 ]
Warren, Zachary [2 ]
Applebaum, Mark A. A. [3 ]
Baroody, Fuad M. M. [2 ,3 ]
机构：
[1] Univ Chicago, Pritzker Sch Med, Chicago, IL USA
[2] Univ Chicago, Dept Surg, Sect Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA
来源：
CASE REPORTS IN ONCOLOGICAL MEDICINE | 2022年 / 2022卷
关键词：
AVASTIN;
D O I：
10.1155/2022/2767996
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recurrent respiratory papillomatosis (RRP) is the most common benign pediatric laryngeal neoplasm. Various adjuvant medical therapies have failed to reliably decrease surgical frequency in this challenging airway disease. Recently, systemic bevacizumab has shown promise in advanced, treatment-resistant papillomatosis. We describe the use of systemic bevacizumab in two children with severe RRP unresponsive to other therapies. Voice and breathing improved dramatically in both patients with minimal side effects. Both patients have not required surgery in 24 months and 16 months, respectively. Systemic bevacizumab is a promising long-term treatment for severe RRP, with oncology playing an important role in patient care.
引用
收藏
页数：3
相关论文
共 20 条
[1]   Opportunities and challenges for successful use of bevacizumab in pediatrics [J].
Barone, Amy ;
Rubin, Joshua B. .
FRONTIERS IN ONCOLOGY, 2013, 3
[2]   Recurrent respiratory papillomatosis: A 2020 perspective [J].
Benedict, Jacob J. ;
Derkay, Craig S. .
LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY, 2021, 6 (02) :340-345
[3]   Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A National Survey [J].
Best, Simon R. ;
Mohr, Michael ;
Zur, Karen B. .
LARYNGOSCOPE, 2017, 127 (10) :2225-2229
[4]   Age at diagnosis, but not HPV type, is strongly associated with clinical course in recurrent respiratory papillomatosis [J].
Buchinsky, Farrel J. ;
Valentino, William L. ;
Ruszkay, Nicole ;
Powell, Evan ;
Derkay, Craig S. ;
Seedat, Riaz Y. ;
Uloza, Virgilijus ;
Dikkers, Frederik G. ;
Tunkel, David E. ;
Choi, Sukgi S. ;
Mortelliti, Anthony J. ;
Campisi, Paolo ;
Ospina, Juan C. ;
Donne, Adam J. ;
Sataloff, Robert T. ;
Conley, Stephen F. ;
McClay, John E. ;
Friedman, Ellen M. ;
Elden, Lisa ;
Tylor, Dale A. ;
Rosen, Clark A. ;
Smith, Libby J. ;
Copley, Graeme J. ;
Karas, David E. ;
Schweinfurth, John M. ;
Myer, Charles M., III ;
Wiatrak, Brian J. ;
Dohar, Joseph E. ;
Sobol, Steven E. ;
Bastian, Robert W. ;
Smith, Richard J. H. ;
Smith, Marshall E. ;
Wassie, Abebe M. ;
Post, James C. ;
Ehrlich, Garth D. .
PLOS ONE, 2019, 14 (06)
[5]   Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children [J].
Carnevale, Claudio ;
Ferran-De la Cierva, Luis ;
Til-Perez, Guillermo ;
Antonio Pena-Zarza, Jose ;
Osona-Rodriguez, Borja ;
Martinez-Lozano, Joaquina ;
Sarria-Echegaray, Pedro ;
Arancibia-Tagle, Diego ;
Tomas-Barberan, Manuel .
LARYNGOSCOPE, 2019, 129 (04) :1001-1004
[6]   Update on Recurrent Respiratory Papillomatosis [J].
Derkay, Craig S. ;
Bluher, Andrew E. .
OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2019, 52 (04) :669-+
[7]   Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: A series of three pediatric cases and literature review [J].
Enrique, Ortiz H. ;
Eloy, Sanchez H. ;
Adrian, Trujillo P. ;
Perla, Villamor .
AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2021, 42 (05)
[8]   Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook [J].
Garcia, Josep ;
Hurwitz, Herbert, I ;
Sandler, Alan B. ;
Miles, David ;
Coleman, Robert L. ;
Deurloo, Regula ;
Chinot, Olivier L. .
CANCER TREATMENT REVIEWS, 2020, 86
[9]   Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: A case report [J].
Hamdi, Osama ;
Dome, Jeff ;
Zalzal, George ;
Preciado, Diego .
INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2020, 128
[10]  
Krstic M., 2014, ACTA MED MEDIANAE, V53, P64, DOI [10.5633/amm.2014.0411, DOI 10.5633/AMM.2014.0411]
12